Table 3.

Lipid-lowering therapy and adherence (medication possession ratio) by sex and age.

Age (years)	LLT	Women, %	Men, %	P-value
8–14	Low-moderate potency	11.8 (14.7%)	10.4 (13.1%)	0.940
	High-very high potency	1.7 (2.1%)	1.0 (1.3%)
	Without LLT	67.0 (83.2%)	68.0 (85.6%)
	MPR	38.8% (35.4%)	50.9% (32.2%)	0.444
15–24	Low-moderate potency	26.5 (23.0%)	17.4 (19.0%)	0.558
	High-very high potency	5.7 (4.9%)	8.3 (9.1%)
	Without LLT	83.0 (72.0%)	66.0 (72.0%)
	MPR	49.5% (28.8%)	47.1% (28.4%)	0.681
25–34	Low-moderate potency	60.1 (29.9%)	76.5 (30.7%)	0.848
	High-very high potency	24.2 (12.0%)	34.8 (14.0%)
	Without LLT	117.0 (58.1%)	138.0 (55.4%)
	MPR	54.5% (26.9%)	49.9% (27.4%)	0.302
35–44	Low-moderate potency	148.4 (37.9%)	381.5 (46.0%)	0.005
	High-very high potency	53.9 (13.8%)	132.1 (15.9%)
	Without LLT	189.0 (48.3%)	315.0 (38.0%)
	MPR	57.6% (27.7%)	55.4% (27.8%)	0.420
45–54	Low-moderate potency	498.8 (61.2%)	688.3 (57.0%)	0.058
	High-very high potency	165.6 (20.3%)	307.3 (25.5%)
	Without LLT	151.0 (18.5%)	211.0 (17.5%)
	MPR	61.1% (28.1%)	64.9% (27.6%)	0.068
55–64	Low-moderate potency	1417.0 (68.9%)	1091.6 (63.8%)	0.000
	High-very high potency	426.8 (20.8%)	495.0 (28.9%)
	Without LLT	213.0 (10.4%)	124.0 (7.2%)
	MPR	66.5% (27.5%)	71.7% (26.8%)	0.000
65–74	Low-moderate potency	1705.3 (74.5%)	1022.7 (63.3%)	0.000
	High-very high potency	488.2 (21.3%)	544.7 (33.7%)
	Without LLT	96.0 (4.2%)	49.0 (3.0%)
	MPR	73.0% (26.2%)	78.4% (24.1%)	0.000
75–84	Low-moderate potency	1121.6 (75.0%)	520.1 (65.6%)	0.002
	High-very high potency	328.0 (21.9%)	250.6 (31.6%)
	Without LLT	45.0 (3.0%)	22.0 (2.8%)
	MPR	76.0% (24.7%)	80.0% (23.1%)	0.033
85 +	Low-moderate potency	384.3 (77.8%)	103.8 (69.4%)	0.139
	High-very high potency	86.5 (17.5%)	42.7 (28.6%)
	Without LLT	23.0 (4.7%)	3.0 (2.0%)
	MPR	73.5% (26.5%)	77.5% (24.9%)	0.362

LLT Lipid lowering therapy, MPR medication possession ratio, LDL-C low-density lipoprotein cholesterol.